Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
PJ Mease, DD Gladman, KA Papp, MM Khraishi… - Journal of the American …, 2013 - Elsevier
… Dr Khraishi received unrestricted educational grants from Pfizer Canada. Dr Thaçi received
honoraria for consultations or speaking engagements from Abbott, Amgen, Astellas, Biogen …
honoraria for consultations or speaking engagements from Abbott, Amgen, Astellas, Biogen …
Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying …
…, O Schieir, A Dooley, B Haraoui, M Khraishi… - The Journal of …, 2012 - jrheum.org
Objective. The Canadian Rheumatology Association (CRA) has developed recommendations
for the pharmacological management of rheumatoid arthritis (RA) with traditional and …
for the pharmacological management of rheumatoid arthritis (RA) with traditional and …
Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying …
…, O Schieir, A Dooley, B Haraoui, M Khraishi… - The Journal of …, 2012 - jrheum.org
Objective. The Canadian Rheumatology Association (CRA) has developed recommendations
for the pharmacological management of rheumatoid arthritis (RA) with traditional and …
for the pharmacological management of rheumatoid arthritis (RA) with traditional and …
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure
…, JS Smolen, J Kremer, M Khraishi… - The Journal of …, 2013 - jrheum.org
Objective. To assess the longterm safety and efficacy of tocilizumab (TCZ) in patients with
moderate to severe rheumatoid arthritis (RA). Methods. Patient data were from 5 randomized …
moderate to severe rheumatoid arthritis (RA). Methods. Patient data were from 5 randomized …
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty‐four–month, phase …
…, H Niall Jones, EC Keystone, M Khraishi… - Arthritis & …, 2019 - Wiley Online Library
Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis ( RA ).
The phase III , 24‐month, placebo‐controlled Oral Rheumatoid Arthritis ( ORAL ) Scan trial …
The phase III , 24‐month, placebo‐controlled Oral Rheumatoid Arthritis ( ORAL ) Scan trial …
CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides
…, A Fifi-Mah, M Goulet, N Khalidi, MM Khraishi… - The Journal of …, 2016 - jrheum.org
Objective. The Canadian Vasculitis research network (CanVasc) is composed of physicians
from different medical specialties and researchers with expertise in vasculitis. One of its aims …
from different medical specialties and researchers with expertise in vasculitis. One of its aims …
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics
…, DD Gladman, P Helliwell, MM Khraishi… - Journal of the American …, 2014 - Elsevier
Background General practitioners/dermatologists may be aware of musculoskeletal symptoms
in patients with psoriasis but may have difficulty accurately detecting psoriatic arthritis (PsA…
in patients with psoriasis but may have difficulty accurately detecting psoriatic arthritis (PsA…
Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts
M Khraishi, D MacDonald, E Rampakakis… - Clinical …, 2011 - Springer
The aim of this study is to describe the comorbidity profile in patients with early and established
psoriatic arthritis (PsA). Patients with PsA were selected from a registry of patients with …
psoriatic arthritis (PsA). Patients with PsA were selected from a registry of patients with …
Prevalence of cardiovascular risk factors in patients with psoriatic arthritis
M Khraishi, R Aslanov, E Rampakakis, C Pollock… - Clinical …, 2014 - Springer
Psoriatic arthritis (PsA) is a chronic T cell-mediated inflammatory spondyloarthropathy
affecting 10–40 % of psoriasis (PSO) patients (0.3–1.0 % of the general population). Recent …
affecting 10–40 % of psoriasis (PSO) patients (0.3–1.0 % of the general population). Recent …
[HTML][HTML] Biosimilars: a multidisciplinary perspective
M Khraishi, D Stead, M Lukas, F Scotte, H Schmid - Clinical therapeutics, 2016 - Elsevier
A biosimilar is an officially regulated and approved copy of an originator biologic therapy.
Improved affordability and consequent wider patient access compared with biologics are a …
Improved affordability and consequent wider patient access compared with biologics are a …